About Lonza Cologne
About Lonza Cologne GmbH: At the Cologne Biocampus, Lonza Bioscience Solutions employees develop and commercialize non-viral gene transfer products for primary cells and difficult-to-transfect cell lines. Primary cells reflect the state and behavior of cells within organisms more accurately than the cell lines usually used in the laboratory. They are therefore important model systems for both basic and clinical research. Using Lonza's Nucleofector® technology, the functionality of different genes in these biologically relevant cell types can be analyzed. The results help to identify potential new pharmaceuticals and therapies, for example to combat cancer or cardiovascular diseases.
About Lonza: Founded in the Swiss Alps in 1897, Lonza is today a market-leading global company with more than 30 major production and research sites and around 19,000 employees worldwide. Lonza's shares are publicly traded on the Swiss and Singapore stock exchanges.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Advertisement
